Clinical Trial Collaboration Announced to Explore Combination Therapy in Patients with Advanced Solid Tumours
The Phase I/IIa clinical trial will evaluate the combination of one of BioInvent’s proprietary anti-TNFR2 antibodies – BI-1808 – with MSD’s anti-PD-1 therapy, KEYTRUDA.
The clinical trial collaboration is reportedly the second of its nature, and includes a supply agreement for the trial.
As Martin Welschof, CEO of BioInvent, explained:
“We are very pleased we have reached a second collaboration with MSD that supports the expansion of the clinical trial program with our anti-TNFR2 antibody BI-1808. The Phase I component is already enrolling patients who receive BI-1808 as a single agent. We are excited about the potential synergistic activity of BI-1808 in combination with pembrolizumab and this agreement supports the strong interest elicited by our broadening pipeline of anti-cancer antibodies.”
BI-1808 is part of BioInvent’s tumour-associated regulatory T cells (Treg)-targeting program. The antibody has been pulled into focus after having been identified as a promising new drug candidate from BioInvent’s F.I.R.S.T™ platform technology. TNFR2 is particularly upregulated on Tregs and has been demonstrated as an important element for tumour expansion and survival, and is therefore recognised as a new and important target for cancer immunotherapies.
The Phase I/IIa trial will evaluate the use of BI-1808 in the treatment of patients with ovarian cancer and non-small cell lung cancer, both on its own as well as in combination with KEYTRUDA. It is further reported that a separate cohort under the Phase IIa component will explore the use of BI-1808 on its own for cutaneous T cell lymphoma.
Patients are already being enrolled in several European countries as the trial is planned to be carried out in the US, Denmark, Hungary, the UK and Russia.